---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-003808"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:12:09.479618+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

## Summary
- Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.
- Net loss $0.8M vs net income $0.1M; diluted EPS $(0.03) vs $0.00.
- Six-month revenue $24.0M vs $26.2M; operating loss $0.7M vs income $0.7M.
- Two largest contract manufacturing customers accounted for ~89% of total revenue.
- Selling and administrative expenses decreased slightly to $0.9M from $1.0M.

## SEC filing metadata
- accession: 0001437749-26-003808
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/0001437749-26-003808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/inbp20260205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-003808
- JSON: https://secwatch.observer/filing/0001437749-26-003808.json
- Plain text: https://secwatch.observer/filing/0001437749-26-003808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.